Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer

By Torrisi Rosalba  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 431-441

Springer Publishing Company

Access to resources Recommend Favorite

Preoperative Therapy Using Trastuzumab and Weekly Paclitaxel in a Stage III B Inoperable Locally Advanced HER2-Positive Breast Cancer with Complete Pathologic Response

By Rai Yoshiaki   Sagara Yoshiatsu   Ooi Yasuyo   Yasuaki   Sagara Yoshiaki   Baba Shinichi   Tamada Syugo   Matsuyama Yoshito   Ando Mitsutake  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 471-473

Sunmedia

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

By Horio Akiyo  

International Journal of Clinical Oncology, Vol. 17, Iss. 2, 2012-04 ,pp. : 131-136

Springer Publishing Company

Access to resources Recommend Favorite